In Silico Prediction of Maize microRNA as a Xanthine Oxidase Inhibitor: A New Approach to Treating Hyperuricemia Patients
- PMID: 39846684
- PMCID: PMC11755550
- DOI: 10.3390/ncrna11010006
In Silico Prediction of Maize microRNA as a Xanthine Oxidase Inhibitor: A New Approach to Treating Hyperuricemia Patients
Abstract
Introduction: Hyperuricemia is characterized by increased uric acid (UA) in the body. The ability to block xanthine oxidase (XO) is a useful way to check how different bioactive molecules affect hyperuricemia. Previous reports showed the significant effect of corn against hyperuricemia disorder with its anti-XO activity. The identification of stable Zea mays miRNA (zma-miR) in humans has opened up a new avenue for speculation about its part in regulating novel human gene targets.
Aims: The aim of this study was to investigate the prospects of zma-miRs in XO gene regulation, the possible mechanism, and the interaction analysis of the zma-miR-XO mRNA transcript.
Method: Significant features of miRNA-mRNA interaction were revealed using two popular miRNA target prediction software-intaRNA (version 3.3.1) and RNA hybrid (version 2.2.1) Results: Only 12 zma-miR-156 variants, out of the 325 zma-miR's sequences reported in the miRNA database, efficiently interact with the 3'UTR of the XO gene. Characteristics of miRNA-mRNA interaction were as follows: the positioning of zma-miR-156 variants shows that they all have the same 11-mer binding sites, guanine (G), and uracil (U) loops at the 13th and 14th positions from the 5' end, and no G: U wobble pairing. These factors are related to the inhibition of functional mRNA expression. Additionally, the zma-miR-156 variants exhibit a single-base variation (SBV), which leads to distinct yet highly effective alterations in their interaction pattern with the XO mRNA transcript and the corresponding free energy values.
Conclusion: Therefore, we propose that zma-miR-156 variants may be a promising new bioactive compound against hyperuricemia and related diseases.
Keywords: base variation; hyperuricemia; maize miRNAs; xanthine oxidase.
Conflict of interest statement
The authors declare no conflict of interest.
Figures


Similar articles
-
Ferulic acid ameliorates hyperuricemia by regulating xanthine oxidase.Int J Biol Macromol. 2023 Dec 31;253(Pt 3):126542. doi: 10.1016/j.ijbiomac.2023.126542. Epub 2023 Aug 26. Int J Biol Macromol. 2023. PMID: 37634782
-
MicroRNA (miRNA) profiling of maize genotypes with differential response to Aspergillus flavus implies zma-miR156-squamosa promoter binding protein (SBP) and zma-miR398/zma-miR394-F -box combinations involved in resistance mechanisms.Stress Biol. 2024 May 10;4(1):26. doi: 10.1007/s44154-024-00158-w. Stress Biol. 2024. PMID: 38727957 Free PMC article.
-
A comprehensive review on recent xanthine oxidase inhibitors of dietary based bioactive substances for the treatment of hyperuricemia and gout: Molecular mechanisms and perspective.Int J Biol Macromol. 2024 Oct;278(Pt 3):134832. doi: 10.1016/j.ijbiomac.2024.134832. Epub 2024 Aug 20. Int J Biol Macromol. 2024. PMID: 39168219 Review.
-
Genetic and Epigenetic Regulation of the Innate Immune Response to Gout.Immunol Invest. 2023 Apr;52(3):364-397. doi: 10.1080/08820139.2023.2168554. Epub 2023 Feb 6. Immunol Invest. 2023. PMID: 36745138 Review.
-
In vitro and In silico Xanthine Oxidase Inhibitory Activities of 3-Aryl-2- thioxo-2,3-dihydroquinazolin-4(1H)-one Derivatives.Med Chem. 2023;19(4):384-392. doi: 10.2174/1573406418666220620124034. Med Chem. 2023. PMID: 35726432
References
-
- Choi H.K., Curhan G. Gout: Epidemiology and lifestyle choices. Curr. Opin. Rheumatol. 2005;17:341–345. - PubMed
LinkOut - more resources
Full Text Sources
Miscellaneous